These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31866261)

  • 1. Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions.
    Wehner MR; Micheletti R; Noe MH; Linos E; Margolis DJ; Naik HB
    J Am Acad Dermatol; 2020 May; 82(5):1239-1241. PubMed ID: 31866261
    [No Abstract]   [Full Text] [Related]  

  • 2. Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: A cross-sectional analysis.
    Orenstein LAV; Wright S; Strunk A; Garg A
    J Am Acad Dermatol; 2021 May; 84(5):1399-1401. PubMed ID: 32758630
    [No Abstract]   [Full Text] [Related]  

  • 3. Low Utilization of the Dermatology Ambulatory Encounter among Patients with Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Analysis in the USA.
    Garg A; Lavian J; Strunk A
    Dermatology; 2017; 233(5):396-398. PubMed ID: 28954266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatology in the emergency department: Prescriptions, rates of inpatient admission, and predictors of high utilization in the United States from 1996 to 2012.
    Yang JJ; Maloney NJ; Bach DQ; Cheng K
    J Am Acad Dermatol; 2021 May; 84(5):1480-1483. PubMed ID: 32687969
    [No Abstract]   [Full Text] [Related]  

  • 5. Hidradenitis suppurativa in black pediatric patients - a national analysis of the kids' inpatient database.
    Singal A; Desai AD; Lipner SR
    Arch Dermatol Res; 2024 Sep; 316(9):616. PubMed ID: 39276244
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis.
    Pham JP; Rosenø NAL; Roccuzzo G; Saal RC; Egeberg A; Ring HC; Frew JW
    J Am Acad Dermatol; 2024 Jul; 91(1):170-172. PubMed ID: 38554939
    [No Abstract]   [Full Text] [Related]  

  • 7. Trends in antibiotic prescriptions for hidradenitis suppurativa from 2015 to 2021.
    Horissian M; Samaan C; Cohrs A; Kirby J
    Br J Dermatol; 2024 Jun; 191(1):142-143. PubMed ID: 38606685
    [No Abstract]   [Full Text] [Related]  

  • 8. Hidradenitis suppurativa-acne inversa: a relevant dermatosis in paediatric patients.
    Bettoli V; Ricci M; Zauli S; Virgili A
    Br J Dermatol; 2015 Nov; 173(5):1328-30. PubMed ID: 26075707
    [No Abstract]   [Full Text] [Related]  

  • 9. [Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].
    Zimman S; Cura MJ; Luna PC; Echeverría CM; Mazzuoccolo LD
    Actas Dermosifiliogr (Engl Ed); 2020 Nov; 111(9):806-807. PubMed ID: 32576376
    [No Abstract]   [Full Text] [Related]  

  • 10. Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.
    Kurti Z; Vegh Z; Golovics PA; Fadgyas-Freyler P; Gecse KB; Gonczi L; Gimesi-Orszagh J; Lovasz BD; Lakatos PL
    Dig Liver Dis; 2016 Nov; 48(11):1302-1307. PubMed ID: 27481587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying musculoskeletal conditions in electronic medical records: a prevalence and validation study using the Deliver Primary Healthcare Information (DELPHI) database.
    Ryan BL; Maddocks HL; McKay S; Petrella R; Terry AL; Stewart M
    BMC Musculoskelet Disord; 2019 May; 20(1):187. PubMed ID: 31053119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
    Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
    Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
    Lee BR; Brostek AR; Kaffenberger BH
    J Am Acad Dermatol; 2024 Jul; 91(1):100-102. PubMed ID: 38490372
    [No Abstract]   [Full Text] [Related]  

  • 14. Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa.
    Shalom G; Babaev M; Freud T; Tiosano S; Pam N; Horev A; Dreiher J; Vardy DA; Comaneshter D; Cohen AD
    J Am Acad Dermatol; 2017 Dec; 77(6):1047-1052.e2. PubMed ID: 28989106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Cohort Study on Patients with Hidradenitis Suppurativa.
    Seyed Jafari SM; Knüsel E; Cazzaniga S; Hunger RE
    Dermatology; 2018; 234(1-2):71-78. PubMed ID: 29758553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of opioid use in sickle cell disease.
    Han J; Zhou J; Saraf SL; Gordeuk VR; Calip GS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):479-486. PubMed ID: 28815799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain Severity and Management of Hidradenitis Suppurativa at US Emergency Department Visits.
    Taylor MT; Orenstein LAV; Barbieri JS
    JAMA Dermatol; 2021 Jan; 157(1):115-117. PubMed ID: 33206135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital.
    Di Pentima MC; Chan S
    Pediatr Infect Dis J; 2010 Aug; 29(8):707-11. PubMed ID: 20182398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provider landscape for hidradenitis suppurativa patients.
    Berman HS; Shi VY; Hsiao JL
    Int J Dermatol; 2020 May; 59(5):e164-e166. PubMed ID: 31736054
    [No Abstract]   [Full Text] [Related]  

  • 20. Indications and classes of outpatient antibiotic prescriptions in Japan: A descriptive study using the national database of electronic health insurance claims, 2012-2015.
    Hashimoto H; Saito M; Sato J; Goda K; Mitsutake N; Kitsuregawa M; Nagai R; Hatakeyama S
    Int J Infect Dis; 2020 Feb; 91():1-8. PubMed ID: 31730926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.